Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 2/20 | 0.56 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.49 |
| ▸ | ECE1 | P42892 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.43 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 2/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP14 | P50281 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2074343 | 0.95 | CTRB1 (0.51) | CTRB1ITGB3ITGA2BECE1CYP3A4 | |
| SCHEMBL4890831 | 0.83 | CTRB1 (0.64) | CTRB1ITGB3ITGA2BECE1CTSL | |
| SCHEMBL3770984 | 0.79 | HTT (0.59) | — | |
| SCHEMBL6318726 | 0.78 | CTRB1 (0.74) | CTRB1ITGB3ITGA2BCYP3A4CTSL | |
| SCHEMBL6320787 | 0.78 | CTRB1 (0.74) | CTRB1ITGB3ITGA2BCYP3A4CTSL | |
| SCHEMBL6318717 | 0.78 | CTRB1 (0.74) | CTRB1ITGB3ITGA2BCYP3A4CTSL | |
| SCHEMBL2076562 | 0.78 | HTT (0.45) | ITGB3ITGA2B | |
| SCHEMBL19386326 | 0.77 | CTRB1 (0.57) | CTRB1ITGB3ITGA2BECE1CTSL | |
| SCHEMBL6093916 | 0.77 | CTRB1 (0.72) | CTRB1CYP3A4CTSLTACR1CTSB | |
| SCHEMBL6093920 | 0.77 | CTRB1 (0.72) | CTRB1CYP3A4CTSLTACR1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216989-B2 | (Poly) aminoacetamide derivatives of epipodophyllotoxin their process of preparation and their applications in therapeutics as anticancer agents | PIERRE FABRE MEDICAMENT (FR) | 2015-12-22 | — | — | US | disclosed |
| US-20110053967-A1 | (POLY) AMINOACETAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN THEIR PROCESS OF PREPARATION AND THEIR APPLICATIONS IN THERAPEUTICS AS ANTICANCER AGENTS | IMBERT THIERRY | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053967-A1 | (POLY) AMINOACETAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN THEIR PROCESS OF PREPARATION AND THEIR APPLICATIONS IN THERAPEUTICS AS ANTICANCER AGENTS | NPEPPS, PTMA, PARN | CTRB1 3136/4885ITGB3 1549/4885ITGA2B 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.